These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334 [TBL] [Abstract][Full Text] [Related]
23. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Demetri GD Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773 [TBL] [Abstract][Full Text] [Related]
24. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. Paniagua RT; Sharpe O; Ho PP; Chan SM; Chang A; Higgins JP; Tomooka BH; Thomas FM; Song JJ; Goodman SB; Lee DM; Genovese MC; Utz PJ; Steinman L; Robinson WH J Clin Invest; 2006 Oct; 116(10):2633-42. PubMed ID: 16981009 [TBL] [Abstract][Full Text] [Related]
25. Acceleration of tumor growth and peri-tumoral blood clotting by imatinib mesylate (Gleevec). Samoszuk M; Corwin MA Int J Cancer; 2003 Sep; 106(5):647-52. PubMed ID: 12866022 [TBL] [Abstract][Full Text] [Related]
26. Marked regression of metastatic pilocytic astrocytoma during treatment with imatinib mesylate (STI-571, Gleevec): a case report and laboratory investigation. McLaughlin ME; Robson CD; Kieran MW; Jacks T; Pomeroy SL; Cameron S J Pediatr Hematol Oncol; 2003 Aug; 25(8):644-8. PubMed ID: 12902920 [TBL] [Abstract][Full Text] [Related]
27. Gleevec/imatinib, an ABL2 kinase inhibitor, protects tumor and endothelial cells from semaphorin-induced cytoskeleton collapse and loss of cell motility. Procaccia V; Nakayama H; Shimizu A; Klagsbrun M Biochem Biophys Res Commun; 2014 May; 448(2):134-8. PubMed ID: 24759231 [TBL] [Abstract][Full Text] [Related]
28. Potential of small molecule protein tyrosine kinase inhibitors as immuno-modulators and inhibitors of the development of type 1 diabetes. Little PJ; Cohen N; Morahan G ScientificWorldJournal; 2009 Mar; 9():224-8. PubMed ID: 19347233 [No Abstract] [Full Text] [Related]
29. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Appel S; Boehmler AM; Grünebach F; Müller MR; Rupf A; Weck MM; Hartmann U; Reichardt VL; Kanz L; Brümmendorf TH; Brossart P Blood; 2004 Jan; 103(2):538-44. PubMed ID: 14504105 [TBL] [Abstract][Full Text] [Related]
30. Imatinib mesylate stimulates low-density lipoprotein receptor-related protein 1-mediated ERK phosphorylation in insulin-producing cells. Fred RG; Boddeti SK; Lundberg M; Welsh N Clin Sci (Lond); 2015 Jan; 128(1):17-28. PubMed ID: 24865476 [TBL] [Abstract][Full Text] [Related]
32. Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Mumprecht S; Matter M; Pavelic V; Ochsenbein AF Blood; 2006 Nov; 108(10):3406-13. PubMed ID: 16873671 [TBL] [Abstract][Full Text] [Related]
33. Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5'-phosphatase interaction with c-Abl. Mokhtari D; Al-Amin A; Turpaev K; Li T; Idevall-Hagren O; Li J; Wuttke A; Fred RG; Ravassard P; Scharfmann R; Tengholm A; Welsh N Diabetologia; 2013 Jun; 56(6):1327-38. PubMed ID: 23462796 [TBL] [Abstract][Full Text] [Related]
34. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. Parmar S; Katsoulidis E; Verma A; Li Y; Sassano A; Lal L; Majchrzak B; Ravandi F; Tallman MS; Fish EN; Platanias LC J Biol Chem; 2004 Jun; 279(24):25345-52. PubMed ID: 15056660 [TBL] [Abstract][Full Text] [Related]
35. Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Parmar S; Smith J; Sassano A; Uddin S; Katsoulidis E; Majchrzak B; Kambhampati S; Eklund EA; Tallman MS; Fish EN; Platanias LC Blood; 2005 Oct; 106(7):2436-43. PubMed ID: 15790787 [TBL] [Abstract][Full Text] [Related]
36. Gleevec inhibits beta-amyloid production but not Notch cleavage. Netzer WJ; Dou F; Cai D; Veach D; Jean S; Li Y; Bornmann WG; Clarkson B; Xu H; Greengard P Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12444-9. PubMed ID: 14523244 [TBL] [Abstract][Full Text] [Related]